Perioperaciina Medicina https://perioperative.org.ua/index.php/prtmdc en-US <p><a href="http://creativecommons.org/licenses/by/4.0/" rel="license"><img src="https://i.creativecommons.org/l/by/4.0/88x31.png" alt="Creative Commons License"></a><br>This work is licensed under a <a href="http://creativecommons.org/licenses/by/4.0/" rel="license">Creative Commons Attribution 4.0 International License</a></p> editor@perioperative.org.ua (Oleksandr Marchuk) vlvitkovskyi@gmail.com (Viktor Vitkovskyi) Mon, 31 May 2021 00:00:00 +0300 OJS 3.3.0.8 http://blogs.law.harvard.edu/tech/rss 60 Principles of using esmolol in the practice of anesthesiologists and intensive care physicians https://perioperative.org.ua/index.php/prtmdc/article/view/56 <p>Prevention and reduction of cardiac risk remains an important issue in anesthesiology and intensive care. There is a successful clinical experience in the use of esmolol for the correction of hemodynamic and ischemic disorders in acute coronary syndrome, in the perioperative period with excessive activation of the sympathoadrenal system. A large number of works are devoted to the use of esmolol as a drug that prevents hemodynamic changes due to tracheal intubation. The aim of the study was to evaluate the use of esmolol and dexmedetomidine as intravenous adjuvants in general analgesia during thyroidectomy in patients with thyrotoxicosis. The use of esmolol (Biblock) and dexmedetomidine in anesthesia for thyroidectomy, suppresses the hemodynamic response caused by surgical stress. Both adjuvants stabilize oxygen consumption and maintain a stable metabolism. Both drugs are quite effective as intravenous adjuvants in general analgesia for thyroidectomy in patients with thyrotoxicosis. They are the drugs of choice and can be recommended in practical anesthesiology.</p> Volodymyr Chernii Copyright (c) 2021 https://creativecommons.org/licenses/by/4.0 https://perioperative.org.ua/index.php/prtmdc/article/view/56 Sat, 22 May 2021 00:00:00 +0300 A clinical view on the possibility and feasibility of using decamethoxin during the COVID-19 pandemic https://perioperative.org.ua/index.php/prtmdc/article/view/57 <p><strong>Background.</strong> Due to the significant spread of the COVID-19 pandemic and the available contact route of transmission, there is a growing interest in the possibility of using antiseptics to prevent contagion of this viral disease. However, the list of antiseptic drugs for local application is limited.</p> <p><strong>The aim:</strong> to investigate the possibility and feasibility of clinical use of decamethoxine as an antiseptic during the infectious COVID-19 pandemic.</p> <p><strong>Materials and methods.</strong> Researches and systematic reviews published between 2001 and 2020 were studied using PubMed and Google Scholar searches.</p> <p><strong>Results.</strong> It is shown that decamethoxine is an active antiseptic drug, the clinical effectiveness of which has been proven in patients with various pathologies (including bronchial and pulmonary diseases). Decamethoxine can be used in various ways, that provides a variety of routes to deliver the drug to the patient, and it has a strong antiviral activity against different groups of viruses.</p> <p><strong>Conclusions.</strong> The analysis demonstrates the feasibility of using decamethoxine solutions to prevent the occurrence and spread of COVID-19 infection.</p> Oleksandr Halushko Copyright (c) 2021 https://creativecommons.org/licenses/by/4.0 https://perioperative.org.ua/index.php/prtmdc/article/view/57 Fri, 21 May 2021 00:00:00 +0300 High-dose N-acetylcysteine therapy in the treatment of pneumonia https://perioperative.org.ua/index.php/prtmdc/article/view/53 <p>The article presents modern data on the use of N-acetylcysteine in the treatment of infectious diseases of the respiratory tract in the practice of a physician. Its antioxidant, mucolytic, anti-inflammatory, pulmoprotective and antitoxic properties are described. The emphasis is placed on the antioxidant properties of N-acetylcysteine, which are expressed when used in high doses of 1200 mg/day or more. There is a review of the literature on the use of high doses of N-acetylcysteine in the treatment of pneumonia, cystic fibrosis, COPD, ARDS. The effect of N-acetylcysteine on individual risk factors for prolonged pneumonia is analyzed. Given the epidemiological situation around the world, the antioxidant properties of N-acetylcysteine in the treatment of pneumonia, including complicated COVID-19, are relevant and require further study.</p> Dmytro Dmytriiev, Oleksandr Nazarchuk, Yuliana Babina Copyright (c) 2021 https://creativecommons.org/licenses/by/4.0 https://perioperative.org.ua/index.php/prtmdc/article/view/53 Thu, 20 May 2021 00:00:00 +0300 Perioperative antibiotic prophylaxis in surgery https://perioperative.org.ua/index.php/prtmdc/article/view/54 <p>Infectious complications in surgery occupy a significant place among the causes of death and increase in the cost of medical care for various pathologies. Antibiotic prophylaxis takes one of the first places in the perioperative period, in addition to surgical treatment and compliance with the rules of asepsis and antiseptics. Laxers is a new drug in the cephalosporin group, consisting of a combination of cefoperazone and sulbactam. It has a wide range of action on gram(-) and anaerobic flora and antistaphylococcal activity, which is not inferior to cefoperazone. Due to sulbactam, it has antimicrobial activity against Pseudomonas aeruginosa and Acinetobacter spp. This article describes the main properties and advantages of Laxers over other cephalosporins in this group as the drug of choice in the treatment of surgical pathologies and alternative antibiotic prophylaxis in the perioperative period in severe patients at risk of contamination of the operating field with hospital flora.</p> Dmytro Dmytriiev, Oleksandr Nazarchuk, Yuliana Babina Copyright (c) 2021 https://creativecommons.org/licenses/by/4.0 https://perioperative.org.ua/index.php/prtmdc/article/view/54 Fri, 28 May 2021 00:00:00 +0300 The use of Decasan in the local treatment of chronic inflammatory diseases of the tonsils https://perioperative.org.ua/index.php/prtmdc/article/view/55 <p>Chronic non-specific inflammatory diseases of the tonsils are predominantly asocialized with bacteria of Streptococcus pyogenes species. However, a mixed microflora, including fungal, is often growing, and tonsillitis can be associated with viral pathogens. Modern antiseptic drug Dekasan, due to its bactericidal, fungicidal, virucidal, sporocidal activity, is a highly effective means for the sanitization of the the palatine tonsils. It can reliably reduce the incidence of tonsillitis, thus reducing the need for systemic antibiotics and will slow the rate of antibiotic resistance.</p> B. N. Bill, A. S. Kushnir Copyright (c) 2021 https://creativecommons.org/licenses/by/4.0 https://perioperative.org.ua/index.php/prtmdc/article/view/55 Sun, 23 May 2021 00:00:00 +0300 Possibilities of using postnatal ultrasound screening of the uropoietic tract https://perioperative.org.ua/index.php/prtmdc/article/view/58 <p>The article provides information on the possibilities of using postnatal ultrasound screening of the uropoietic tract illustrated by the results of using this method in the Slovak Republic. Its main task is to identify malformations of the uropoietic system that were not diagnosed during prenatal diagnosis. The most clinically significant malformations of the kidneys are associated with impaired urine flow (obstructive uropathy). Patients with these malformations often require surgical intervention in the neonatal period or in early childhood. Early diagnosis and timely correction of obstructive uropathy allows maintaining the normal functioning and morphological integrity of the kidneys, preventing the development of chronic kidney disease, improving the quality and life expectancy of patients. Thus, the costs of screening research are incommensurate with the consequences of an untimely diagnosed pathology and the treatment of complications such as chronic kidney disease, kidney failure, recurrent urinary tract infections (antibiotic therapy, hemodialysis, etc.).</p> Kateryna Dmytriieva, Dmytro Dmytriiev Copyright (c) 2021 https://creativecommons.org/licenses/by/4.0 https://perioperative.org.ua/index.php/prtmdc/article/view/58 Tue, 25 May 2021 00:00:00 +0300